Eton Pharmaceuticals, Inc. (ETON) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to the Eaton Pharmaceuticals First Quarter 2026 Financial Results Conference Call. At this time, all participants are in listen-only mode. Following the formal remarks, we will open the call up for your questions. Please revise that this call is being recorded at the company's request. At this time, I'd like to turn it over to David Krimpa, Chief Business Officer at Eaton Pharmaceuticals. Please proceed. Thank you, Operator. Good afternoon, everyone, and welcome to Eaton's first quarter 2026 conference call. This afternoon, we issued a press release that outlines the topics we plan to discuss on today's call. The release is available on our website, eatonfarming.com. Joining me on our call today, we have Shondra Jelson, our CEO, James Gruber, our CFO, Judy Matthews, our Executive Vice President of Finance, and Ipek Trinkaus, our Chief Commercial Officer. In addition to taking live questions on today's call, we will also be answering questions that are emailed to us. Investors can send their questions to investorrelations at eatonfarmer.com. Before we begin, I would like to remind everyone that remarks made during the call may contain forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those contained in these forward-looking statements. Please see the forward-looking statements disclaimer in our earnings release and the risk factors in the company's filings with the FCC. Now, I will turn the call over to our CEO, Sean Brangelson. Thank you, David. Good afternoon, everyone, and thank you for joining us today. The first quarter was another great quarter for Eaton. We achieved record product sales delivering 73% year-over-year product revenue growth. We launched two new maj...